Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Oncogene

• Publication date

  2013-02-28

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1038/onc.2012.136PMID 22525277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells.

  2010cited by this paper
• Antiproliferative Effects of CC-8062 and CC-8075 in Pancreatic Cancer Cells

  2009cited by this paper
• Functional characterization of phosphodiesterases 4 in the rat carotid body: effect of oxygen concentrations.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Targeted therapies in the treatment of advanced/metastatic NSCLC.

  2009cited by this paper
• Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer

  2009cited by this paper
• Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4.

  2009cited by this paper
• Recent developments of targeted therapies in the treatment of non-small cell lung cancer.

  2009cited by this paper
• Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia

  2008cited by this paper
• Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression

  2008cited by this paper
• Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

  2007cited by this paper
• Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts

  2007cited by this paper
• Overview of PDEs and Their Regulation

  2007cited by this paper
• Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

  2007cited by this paper
• Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.

  2007cited by this paper
• A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.

  2007cited by this paper
• Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells.

  2006cited by this paper
• Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

  2006cited by this paper
• Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia‐inducible factor 1

  2006cited by this paper
• Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer.

  2006cited by this paper
• HIF-1alpha attenuates tumor growth in spite of augmented vascularization in an A549 adenocarcinoma mouse model.

  2005cited by this paper
• Integration of Oxygen Signaling at the Consensus HRE

  2005cited by this paper
• Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

  2005cited by this paper
• Activation of Protein Kinase G Is Sufficient to Induce Apoptosis and Inhibit Cell Migration in Colon Cancer Cells

  2004cited by this paper
• Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility

  2004cited by this paper
• Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.

  2003cited by this paper
• Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia.

  2003cited by this paper
• Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling*

  2003cited by this paper
• Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.

  2002cited by this paper
• Hypoxia — a key regulatory factor in tumour growth

  2002cited by this paper
• Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP.

  2002cited by this paper
• The Type IV Phosphodiesterase Inhibitor Rolipram Induces Expression Inhibitors p21Cip1 and p27Kip1, Resulting in Growth Inhibition, Increased Differentiation, and Subsequent Apoptosis of Malignant A-172 Glioma Cells

  2002cited by this paper
• Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer.

  2000cited by this paper
• Cyclic 3',5'-nucleotide phosphodiesterases: potential targets for anticancer therapy.

  2000cited by this paper

• Roflumilast reduces the number of lung adenocarcinomas, inflammation, and emphysema in a smoking-induced mouse model

  2025cites this paper
• PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges

  2025cites this paper
• Comparative Copy Number Variation Profiling of GL01, an Immortalized Non-small Cell Lung Cancer Cell Line Derived from a Filipino Patient, and A549 Lung Adenocarcinoma Cells

  2025cites this paper
• PDE4B Inhibition: Exploring the Landscape of Chemistry Behind Specific PDE4B Inhibitors, Drug Design, and Discovery

  2025cites this paper
• The multifaceted role of phosphodiesterase 4 in tumor: from tumorigenesis to immunotherapy

  2025cites this paper
• Role of exchange proteins directly activated by cAMP signaling in vascular remodeling.

  2025cites this paper
• cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment

  2024cites this paper
• Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present)

  2024cites this paper
• Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.

  2024cites this paper
• Promising candidate drug target genes for repurposing in cervical cancer: A bioinformatics-based approach

  2024cites this paper
• Machine Learning Integration with Single-Cell Transcriptome Sequencing Datasets Reveals the Impact of Tumor-Associated Neutrophils on the Immune Microenvironment and Immunotherapy Outcomes in Gastric Cancer

  2024cites this paper
• Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate

  2023cites this paper
• MiR-149-5p inhibits cell proliferation, promotes cell apoptosis and retards cell cycle of IL-22-stimulated HaCaT and NHEK keratinocytes via regulating PDE4D.

  2023cites this paper
• Rolipram suppresses migration and invasion of human choriocarcinoma cells by inhibiting phosphodiesterase 4‐mediated epithelial‐mesenchymal transition

  2023cites this paper
• Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France

  2023cites this paper
• Identification of the shared gene signatures and molecular mechanisms between multiple sclerosis and non-small cell lung cancer

  2023cites this paper
• PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes.

  2023cites this paper
• Inhibition of phosphodiesterase 4D suppresses mTORC1 signaling and pancreatic cancer growth

  2023cites this paper
• Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models

  2023cites this paper
• Primary cilia control oligodendrocyte precursor cell proliferation in white matter injury via Hedgehog-independent CREB signaling

  2023cites this paper
• Development and evaluation of a polygenic risk score for lung cancer in never‐smoking women: A large‐scale prospective Chinese cohort study

  2023cites this paper
• PDE4 inhibitors for disease therapy: advances and future perspective.

  2023cites this paper
• Knockdown of NUPR1 inhibits angiogenesis in lung cancer through IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways

  2023cites this paper
• Pan-cancer analysis of the PDE4DIP gene with potential prognostic and immunotherapeutic values in multiple cancers including acute myeloid leukemia

  2023cites this paper
• PDE4D binds and interacts with YAP to cooperatively promote HCC progression.

  2022cites this paper
• Apremilast in Psoriasis Patients With Serious Comorbidities: a Case Series and Systematic Review of Literature

  2022cites this paper
• Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system

  2022cites this paper
• Editorial: Signaling pathways behind immune evasion and therapy resistance

  2022cites this paper
• The regulatory role of PDE4B in the progression of inflammatory function study

  2022cites this paper
• Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases

  2022cites this paper
• Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers

  2022cites this paper
• A nonneglectable stereochemical factor in drug development: Atropisomerism.

  2022cites this paper
• Epac: A Promising Therapeutic Target for Vascular Diseases: A Review

  2022cites this paper
• Cyclic‐AMP signalling, MYC and hypoxia‐inducible factor 1α intersect to regulate angiogenesis in B‐cell lymphoma

  2022cites this paper
• cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach

  2022cites this paper
• Integrative Analyses of Circulating mRNA and lncRNA Expression Profile in Plasma of Lung Cancer Patients

  2022cites this paper
• Malignancy Risks of Dermatologic Therapies

  2021cites this paper
• Potential Cancer- and Alzheimer’s Disease-Targeting Phosphodiesterase Inhibitors from Uvaria alba: Insights from In Vitro and Consensus Virtual Screening

  2021cites this paper
• Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25+/CD54+ NK cells

  2021cites this paper
• mGWAS identification of six novel single nucleotide polymorphism loci with strong correlation to gastric cancer

  2021cites this paper
• Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

  2021cites this paper
• LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling

  2021cites this paper
• Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance

  2021cites this paper
• Novel molecules containing structural features of NSAIDs and 1,2,3-triazole ring: Design, synthesis and evaluation as potential cytotoxic agents

  2021cites this paper
• Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma

  2021cites this paper
• Antiproliferative, cholinesterase and phosphodiesterase inhibitory activity of the DCM sub-extract of Uvaria alba: In vitro and in silico perspectives

  2020cites this paper
• Hypoxia and the hypoxia inducible factor 1α activate protein kinase A by repressing RII beta subunit transcription

  2020cites this paper
• Synthesis, antitumor activity, and molecular docking study of 2-cyclopentyloxyanisole derivatives: mechanistic study of enzyme inhibition

  2020cites this paper
• The use of new quinazolinone derivative and doxorubicin loaded solid lipid nanoparticles in reversing drug resistance in experimental cancer cell lines: A systematic study

  2020cites this paper
• PDE4 subtypes in cancer

  2020cites this paper
• Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer

  2020cites this paper
• Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.

  2020cites this paper
• Constructing gene regulatory networks using epigenetic data

  2020cites this paper
• Complex roles of cAMP–PKA–CREB signaling in cancer

  2020cites this paper
• Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids

  2020cites this paper
• Antiproliferative, Anticholinesterase and Anti-Phosphodiesterase Inhibitory Properties of the DCM Sub-Extract of Uvaria Alba: Evidence from in Silico Target Fishing and in Vitro Testing

  2020cites this paper
• Psoriasis in Patients With Active Lung Cancer: Is Apremilast a Safe Option?

  2019cites this paper
• Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.

  2019cites this paper
• High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma

  2019cites this paper
• Cancer Stem Cells: «Emergency Service» for Tumors Under Generalized Cellular Stress

  2019cites this paper
• Triazole‐Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells

  2019cites this paper
• Molecular Networking Reveals the Chemical Diversity of Selaginellin Derivatives, Natural Phosphodiesterase-4 Inhibitors from Selaginella tamariscina.

  2019cites this paper
• Hypoxia-Dependent Angiogenesis and Lymphangiogenesis in Cancer.

  2019cites this paper
• The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway

  2019cites this paper
• Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.

  2019cites this paper
• Gastric cancer may share genetic predisposition with esophageal squamous cell carcinoma in Chinese populations

  2018cites this paper
• Cancer Stem Cells: Emergent Nature of Tumor Emergency

  2018cites this paper
• Genomic pro fi ling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identi fi es germline variants with prognostic value in SMYD 2

  2018cites this paper
• Cellular density‐dependent increases in HIF‐1α compete with c‐Myc to down‐regulate human EP4 receptor promoter activity through Sp‐1‐binding region

  2018cites this paper
• Leptin induces the expression of tumorigenic genes in the gastric mucosa of male Sprague-Dawley rats

  2018cites this paper
• Anagrelide for Gastrointestinal Stromal Tumor

  2018cites this paper
• miR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D.

  2018cites this paper
• miR-203 a-3 p promotes colorectal cancer proliferation and migration by targeting PDE 4 D

  2018cites this paper
• Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

  2018cites this paper
• Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

  2018cites this paper
• Inhibitors of phosphodiesterase as cancer therapeutics.

  2018cites this paper
• Optogenetics in cancer drug discovery

  2018cites this paper
• East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease

  2018cites this paper
• Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer

  2018cites this paper
• Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

  2018cites this paper
• Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment

  2018cites this paper
• Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update

  2018cites this paper
• Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer

  2018cites this paper
• Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.

  2018cites this paper
• PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma

  2017cites this paper
• Epac1, PDE4, and PKC protein expression and their correlation with AKAP95 and Cx43 in esophagus cancer tissues

  2017cites this paper
• PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer.

  2017cites this paper
• Rolipram potentiates bevacizumab‐induced cell death in human glioblastoma stem‐like cells

  2017cites this paper
• Increase of Intracellular Cyclic AMP by PDE4 Inhibitors Affects HepG2 Cell Cycle Progression and Survival

  2017cites this paper
• A 9-cisz retinsav és a mitotán tumorellenes hatásainak és a mikroRNS kifejeződés mintázatának vizsgálata mellékvesekéreg-rák xenograft modelljein

  2017cites this paper
• The Role of Protein Kinase B Signaling Pathway in Anti-Cancer Effect of Rolipram on Glioblastoma Multiforme: An In Vitro Study

  2017cites this paper
• Transcription Factor Trps1 Promotes Tubular Cell Proliferation after Ischemia-Reperfusion Injury through cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D and AKT.

  2017cites this paper
• Lung cancer–associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell–immune cell cross-talk

  2017cites this paper
• Development of anticancer agents targeting the Hedgehog signaling

  2017cites this paper
• 1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.

  2017cites this paper
• Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene‐induced murine lung cancer model

  2017cites this paper
• c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma

  2016cites this paper
• The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

  2016cites this paper
• Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation

  2016cites this paper
• Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling

  2016cites this paper